Myriad Logo
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us

Category: GeneSight

GeneSight
  • Category
    • All
    • Breast Cancer
    • Corporate
    • Financial
    • GeneSight
    • Hereditary Cancer
    • Ovarian Cancer

Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial

July 12, 2022

Study showed PGx testing helps clinicians prescribe fewer medications with gene-drug interactions Major Depressive Disorder (MDD) remission rates were signif...

Continue Reading
  • Payers
    • Overview
  • Investors
    • Investor Relations
    • Events & Presentations
    • Investor Day
  • News
    • Press Releases
    • Email Alerts Subscription
    • Myriad Genetics Blog
  • Careers
    • Joining the Team
Myriad Logo

Health. Illuminated.

  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Notice of Privacy Practices
  • Language Assistance
  • Cookie Preferences
  • © 2023 Myriad Genetics, Inc.